In shock move, EU panel rejects Alzheimer's drug Leqembi
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh
PDURS explained: The FDA’s new framework for adding software...
The US FDA has recently proposed a new draft framework that enables pharma manufacturers to add software to a drug label if they can demonstrate that the software adds clinical benefit to t
Rare diseases: the urgent need for health equity and acceler...
Rare diseases are complex, but the need is urgent. Alexion’s Eunice Alvazzi discusses the shared responsibility in achieving access to innovation in rare diseases
Rare Disease Diagnostics: Advancing Orphan Drug Development ...
This white paper is free and can be downloaded and read at your convenience
Patient engagement throughout the product lifecycle
One of the things that makes patient engagement for pharma companies so challenging is that it's not something that can be added to one step of a process and then checked off the list.
Digital health innovation: Applications across the patient j...
Digital health innovation (DHI) is a growing category of technologies that connect healthcare stakeholders and improve patient experiences and outcomes.
Novo Nordisk seeks to target heart disease with Cardior acqu...
Cardior CSO will speak at the Oligonucleotide Therapeutics and Delivery conference following announcement of a buyout by Novo Nordisk to enhance their
6th Inflammasome Therapeutics Summit
In the rapidly evolving field of inflammasome therapeutics, the need for innovative approaches to overcome the preclinical and clinical hurdles is more critical than ever.
